Journey Medical Secures Third GPO Contract to Cover 150M Commercial Lives for Emrosi
Journey Medical Corporation expanded payer access for Emrosi™ from 100 million to over 150 million commercial lives by contracting with the third major group purchasing organization on April 1, 2026. This increase covers about 85% of US commercial lives and should drive prescription growth and profitability.
1. Payer Access Expansion
On April 1, 2026, Journey Medical secured a contract with the third major group purchasing organization, expanding Emrosi™ access from 100 million to over 150 million commercial lives, covering around 85% of US commercial lives.
2. Commercial Growth Outlook
This expanded access is expected to drive higher prescription demand as the company focuses on converting payer access into formulary coverage across national and regional health plans through 2026.
3. Profitability Improvement
As formulary adoption increases, Journey Medical anticipates reduced reliance on its co-pay bridging program and improved brand profitability, positioning Emrosi™ for sustained commercial growth in the rosacea market.